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Abstract 
Formulation of a convenient dosage form for administration, by considering 
swallowing difficulty and poor patient compliance, leads to development of 
orally disintegrating tablets. This are also called as orodisperse, mouth 
dissolving, rapidly disintegrating, and fast melt system. This disintegrates in 
the mouth in seconds without chewing and the need of water which is 
advantageous mainly for pediatrics, geriatrics and patients having difficulty 
in swallowing tablets and capsules. Conventional preparation methods are 
spray drying, freeze drying, direct compression, Molding, and sublimation 
while new technologies have been developed for the production of 
orodispersible tablets. This review depicts conventional and recent 
technologies that are used to prepare orodispersible tablets in detail. 
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Introduction  
Oral dosage forms like tablets and capsules possessing 
great problem of swallowing mainly for pediatrics, 
geriatrics, and bedridden, nauseous or non-compliant 
patients’. Orally disintegrating dosage forms has to be 
placed in mouth and then get dispersed in saliva 
without the need of water [1, 2]. Orally disintegrating 
tablets are also called as orodisperse, mouth dissolving, 
rapidly disintegrating, fast melt, and quick dissolve 
system. From past decade, there has been an increased 
demand for more patient-friendly and compliant dosage 
forms. As a result, the demand for developing new 
technologies has been increasing day by day [3]. 
United States Food and Drug Administration (FDA) 
define orally disintegrating tablets as “A solid dosage 
form which contain a medicinal substance or active 
ingredient which disintegrates rapidly within a matter 
of seconds when placed upon a tongue” [4]. US Food 
and Drug Administration  Center  for  Drug  Evaluation  
 
 
 
and Research (CDER) defines, in the ‘Orange Book’, 
an ODT as “a solid dosage form containing medicinal 
substances, which disintegrates rapidly, usually within 
a matter of seconds, when placed upon the tongue”[5]. 
European Pharmacopoeia described orally 
disintegrating tablets as ‘uncoated tablets intended to 
be placed in the mouth where they disperse rapidly 
before being swallowed’ and as tablets which should 
disintegrate within 3 min [6]. About 35% of the general 
population in addition to 30-40% of elderly 
institutionalized patients and 18-22% of all persons in 
long term care facilities suffer from dysphagia, i.e. 
difficulty in swallowing [7]. Orally disintegrating 
tablets have been found to be the choice for Psychiatric 
as well as patient suffering from stroke, thyroid 
disorder, Parkinson’s diseases and multiple sclerosis, 
patients with nausea, vomiting and motion sickness [8].  
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Advantages of an orally disintegrating drug delivery 
system [9, 10]  
• Improved patient compliance.  
• Rapid onset of action and may offer an 
improved bioavailability.  
• Useful for pediatric, geriatric and psychiatric 
patients.  
• Suitable during traveling where water is may 
not be available. 
• No specific packaging required, can be 
packaged in push through blisters.  
• Smooth mouth feel and pleasant taste.  
• Conventional manufacturing equipment. 
• Cost effective. 
• Good chemical stability as conventional oral 
solid dosage form. 
•  
Characteristics of an ideal orally disintegrating 
drug delivery system [10] 
Orally disintegrating drug delivery system should 
possess following characteristics: 
• Utilizes cost effective production method. 
• Require no water for oral administration. 
• Dissolve / disperse/ disintegrate in mouth in a 
matter of seconds.  
• Have a pleasing mouth feel and taste masking.  
• Less friable and have sufficient hardness. 
• Leave minimal or no residue in mouth after 
administration. 
• Manufacturing using conventional 
manufacturing method. 
•  
Choice of drug candidate [3] 
Suitable drug candidate for orally disintegrating tablet 
should posses: 
• No bitter taste. 
• Good stability in water and saliva. 
• Dose should be low as possible. 
Unsuitable drug candidate for orally disintegrating 
tablet should include: 
• Short half-life and frequent dosing. 
• Drug having very bitter taste. 
• Required controlled or sustained release.  
 
Taste masking 
Taste masking is very essential so as to mask the bitter 
taste of most of the drugs. Number of techniques are 
developed for masking the bitter taste of most of the 
drugs, that includes formation of pellets by extrusion, 
spheronization or mass extrusion [11], coating of drug 
using a taste masking polymer [12, 13], spray drying 
the drug dispersed in a polymeric solution [14], 
complexation of drug by inclusion in cyclodextrin [15, 
16], drug-resinate complex formation [17, 18], 
microencapsulation of drug by polymer [19]. 
 
Techniques in preparation of orally disintegrating 
drug delivery system 
The various technologies are developed for the 
preparation of Orally Disintegrating Drug Delivery 
System that are: 
• Freeze drying 
• Spray drying 
• Molding 
• Phase transition process 
• Melt granulation 
• Sublimation 
• Mass Extrusion 
• Cotton Candy Process 
• Direct compression 
 
Freeze drying 
Lyophilization means drying at low temperature under 
condition that involves the removal of water by 
sublimation. Drug in a water soluble matrix which is 
then freeze dried to give highly porous structure. The 
tablets prepared by lyophilization disintegrate rapidly 
in less than 5 seconds due to quick penetration of saliva 
in pores when placed in the oral cavity. Lyophilization 
is useful for heat sensitive drugs i.e. thermo-labile 
substances [20, 21].  
Ahmed et al. prepared lyophilized tablet using freeze 
drying technique. The lyophilized tablet prepared by 
dispersing drug Ketoprofen in aqueous solution of 
highly water soluble carrier consisting of gelatin, 
glycine and sorbitol in blister packs and then subjected 
to lyophillization in blister packs. It was found that the 
increase in solubility of ketoprofen from lyophilized 
tablet matrix was nearly three times greater than 
solubility of the plain drug which was due to 
supersaturation generated by amorphous form of drug 
[22]. 
 
Spray drying 
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Spray drying can produce highly porous and fine 
powders that dissolve rapidly. This technique is based 
on a particulate support matrix, which is prepared by 
spray drying an aqueous composition containing 
support matrix and other components to form a highly 
porous and fine powder. This then mixed with active 
ingredients and compressed into tablets. The 
formulations are incorporated by hydrolyzed and non 
hydrolyzed gelatins as supporting agents, mannitol as 
bulking agent, sodium starch glycolate or 
crosscarmellose sodium as disintegrating and an acidic 
material (e.g. citric acid) and / or alkali material (e.g. 
sodium bicarbonate) to enhance disintegration and 
dissolution. Tablet compressed from the spray dried 
powder disintegrated within 20 seconds when 
immersed in an aqueous medium. 
Allen et al. used a spray drying technique to prepare 
fast dissolving tablets. The tablets made from this 
technology are claimed to disintegrate within 20 
seconds [23]. 
 
Molding 
Tablets prepared by this method are solid dispersions. 
Molded tablets offer improved taste due to water-
soluble sugars present in dispersion matrix. 
Different molding techniques can be used to prepare 
mouth-dissolving tablets:  
a. Compression molding: The manufacturing process 
involves moistening the powder blend with a hydro-
alcoholic solvent followed by compressing into mold 
plates to form a wetted mass which is then air dried to 
remove the solvent. Such tablets are less compact than 
compressed tablets and possess a porous structure that 
hastens dissolution. 
b. Heat molding: A molten matrix in which drug is 
dissolved or dispersed can be directly molded into 
orodispersible tablets. The tablets prepared using heat 
molding process involves settling of molten mass that 
contain a dispersed or dissolved drug [24]. In this 
process, the suspension or solution of drug, agar and 
sugar is prepared and then poured into the blister 
packaging. The agar solution is then solidified at room 
temperature to form a jelly and dried at 30 0C under the 
vacuum. Developed orally disintegrating tablets was 
found to improve the mouth feel due to the presence of 
the water soluble sugars [25]. 
c. No vacuum lyophilization: This process involves 
evaporation of solvent from a drug solution or 
suspension at a standard pressure.  
Molded tablets had less mechanical strength. Drug can 
be present as micro particles or discrete particles 
dispersed in the matrix. However, adding sucrose, 
acacia or polyvinyl pyrrolidone can increase 
mechanical strength. They possess highly porous 
structure which is supposed to increase their 
disintegration and dissolution rates [26]. 
 
Phase transition process 
The combination of low and high melting point sugar 
alcohols, as well as a phase transition in the 
manufacturing process, is important for making orally 
disintegrating tablets without any special apparatus. 
Here, tablet produced by compressing the powder 
containing two sugar alcohols of high and low melting 
point and subsequently heating at temperature between 
their two melting points.Orally disintegrating tablets 
were produced by compressing powder containing 
erythritol (melting point: 122 °C) and xylitol (melting 
point: 93-95 °C), and then heating at about 93 °C for 
15 min. After heating, the median pore size of the 
tablets was increased and tablet hardness was also 
increased. The increase of tablet hardness with heating 
and storage did not depend on the crystal state of the 
lower melting point sugar alcohol. 
Kuno et al. studied the effect of preparation method on 
the properties of orally disintegrating tablets 
manufactured using phase transition of sugar alcohol.  
Before heating process, tablet did not have sufficient 
hardness because of low compatibility but after 
heating, increase in interparticular bonding or binding 
surface area occurs which then increased tablet 
hardness [27]. 
 
Melt granulation 
Abdelbary et al. prepared orally disintegrating tablet by 
incorporating a hydrophilic waxy binder PEG 6-
stearate (Superpolystate®) in the formulation. It has 
melting point of 33-37 0C and HLB value of 9. It acts 
as a binder and increases the physical resistance of 
tablet. It helps for fast disintegration of tablet when 
place in mouth and leaving no residue in oral cavity 
[28].  
Perissutti et al. developed the orally disintegrating 
tablets of Carbamazepine by melt granulation 
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technique. The granules were prepared by using 
polyethylene glycol (PEG-4000) as a melting binder 
and lactose monohydrate as hydrophilic filler without 
using solvents or water. The dissolution profiles of 
granules containing crosspovidone as an 
intragranulating agent were found to be superimposable 
to those prepared without it. Also, the extragranular 
addition of a small amount of crosspovidone gave rise 
to a further increase in disintegration rate and 
dissolution performances. [29]. 
 
Sublimation: 
This technique is based on the use of volatile 
ingredients (e.g. camphor, ammonium bicarbonate, 
naphthalene, urea, urethane etc.) to other tablet 
excipients and the mixture is then compressed into 
tablets. Entrapped volatile material is then removed via 
sublimation, which leads to formation of a porous 
structure. These compressed tablets which have high 
porosity (approximately 30%) rapidly dissolved within 
15 seconds in saliva. Several solvents like cyclohexane, 
benzene etc. can also be used as pore forming agents. 
Orodispersible tablets with highly porous structure and 
good mechanical strength have been developed by this 
method. 
Koizumi et al. prepared highly porous compressed 
tablets. They used mannitol as a tablet matrix material 
while camphor as subliming agent.  Camphor was 
removed by subliming in vacuum at 800C for 30 
minutes to develop pores in the tablets [30].  
Makino et al. described a method of producing a fast 
dissolving tablet using water as a pore forming 
material. They used a mixture containing active 
ingredient and carbohydrates (glucose, mannitol, 
xylitol etc) which then moistened with water (1-3 
%w/w) and compressed into tablets. Then water was 
removed, yielding highly porous tablet [31].  
 
Mass Extrusion 
In this technique, a blend of active drug and other 
ingredients is softened using solvent mixture of water 
soluble polyethylene glycol, using methanol and then 
softened mass is extruded through the extruder or 
syringe to get a cylinder of product, which is finally cut 
into even segments with the help of heated blades to 
get tablets. The dried cylinder can be used to coat the 
granules of bitter tasting drugs and thereby masked 
their bitter taste [32]. 
 
Cotton Candy Process 
This process utilizes a unique spinning mechanism to 
produce floss-like crystalline structure. Cotton candy 
process involves formation of matrix of 
polysaccharides or saccharides by simultaneous action 
of flash melting and spinning. The matrix formed is 
partially recrystallized to improve flow property and 
compressibility. This candy floss matrix is then milled 
and blended with active ingredients and excipients and 
subsequently compressed to orally disintegrating tablet. 
This process can accommodate larger drug doses and 
offers improved mechanical strength. However, high-
process temperature limits the use of this process [33]. 
 
Direct compression 
This is most popular technique because of its easy 
implementation and cost-effectiveness. The basic 
principle involves addition of disintegrants and/or 
water soluble excipients and/or effervescent agents. 
Superdisintegrants in optimum concentration (about 2-
5%) are mostly used so as to achieve rapid 
disintegration along with the good mouth feel. 
Bi et al. examined the disintegrant property of mixture 
of microcrystalline cellulose and low substituted 
hydroxy propyl cellulose (MCC: L-HPC) for orally 
disintegrating tablet and found that shortest 
disintegration time was observed in the range of ratio 
of MCC: L-HPC (8:2 to 9:1) [34]. 
Cousin et al. prepared orally disintegrating tablet using 
carboxymethyl cellulose as disintegrating agent and 
swelling agent consisting of modified starch or 
microcrystalline cellulose. The tablets disintegrate in 
the mouth in less than 60 seconds [35]. 
Gillis et al. prepared a fast-dissolving tablet of 
Galanthamine hydrobromide which comprise of diluent 
which is a spray dried mixture of lactose monohydrate 
and microcrystalline cellulose in the ratio of 75:25, a 
cross linked polymeric disintegrant such as 
crosspovidone and a direct compression process was 
used for preparation of fast dissolving tablets [36].  
Gattani et al. prepared Ondansetron mouth dissolving 
tablet using treated agar as a superdisintegrating agent 
and found that tablets with treated agar powder had 
disintegration rate comparable to other 
superdisintegrants [37]. 
 
Patented technologies for orally disintegrating drug 
delivery system 
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The various technologies are developed for the 
preparation of Orally Disintegrating Drug Delivery 
System that are: 
• Zydis 
• Lyoc 
• Wowtab 
• Flashtab 
• Durasolv 
• Orasolv 
• Frosta 
• AdvaTab 
• Flashdose 
• OraQuick 
• Nanocrystal Technology 
• Quick-Dis Technology 
• EFVDAS 
• Fast Melt  
• Multiflash 
 
Zydis® (Cardinal Health Inc.) 
Zydis® was first marketed technology and introduced 
by R. P. Scherer Corporation (Cardinal Health, Inc.) in 
1986. Zydis tablet is produced by lyophilizing the drug 
in a matrix usually consisting of gelatin. The product is 
very lightweight and fragile and must be dispensed in a 
special blister pack. Zydis formulation is also self-
preserving because the final water concentration in the 
freeze-dried product is too low to allow for microbial 
growth [21]. 
Disadvantages to the Zydis® technology-  
• Relatively expensive & time consuming 
manufacturing process. 
• Formulation is very lightweight and fragile. 
• Poor stability at higher temperatures and 
humidity & stress conditions.  
• A water insoluble drug can be incorporated 
only upto 400 mg per tablet or less. On the 
other hand water soluble drug can be 
incorporated only upto 60 mg. 
The preferred drugs are water insoluble, low dose, 
chemically stable, small particle size and tasteless. The 
two most commonly used structural additives are 
gelatin and mannitol. Some other structural additives 
(e.g., starches, gums etc.) may be used depending on 
the properties of the active ingredient. The best 
physical characteristics are achieved by using a mixture 
of a water-soluble polymer and a crystalline sugar 
alcohol or amino acid. The polymer gives the strength 
and resilience while the crystalline component gives 
the hardness and texture. Polymers such as gelatin, 
dextran or alginates are added to impart strength during 
handling. These form a glossy and amorphous 
structure. Mannitol or sorbitol is added to impart 
crystallinity, elegance and hardness. Various gums may 
be added to prevent sedimentation of dispersed drug 
particles. Water is used as a medium to ensure the 
formation of a porous dosage form. Collapse 
protectants like glycine may be used to prevent 
shrinkage of dosage form during freeze drying and 
long-term storage. If necessary, suspending agents and 
pH adjusting agents may be used [21]. 
 
Lyoc (Cephalon Corporation) 
Lyoc technique was owned by Cephalon Corporation. 
Lyoc utilizes a freeze drying process but differ from 
Zydis in that the product is frozen on the freeze dryer 
shelves. The liquid solution or suspension preparation 
evolves fillers, thickening agents, surfactant, non-
volatile flavoring agents and sweeteners along with 
drug. This homogeneous liquid is placed in blister 
cavities and subjected to freeze drying. To prevent 
inhomogeneity by sedimentation during this process, 
these formulations require a large proportion of 
undissolved inert filler (mannitol), to increase the 
viscosity of the inprocess suspension. The high 
proportion of filler reduces the potential porosity of the 
dried dosage form and results in denser tablets with 
disintegration rates are comparable to loosely 
compressed fast melt formulations [38]. 
 
Wowtab (Yamanouchi Pharma Technologies, Inc.) 
Wowtab technology was developed by Yamanouchi 
Pharma Technologies. ‘Wow’ means ‘without water’. 
The active ingredients may constitute upto 50% w/w of 
the tablet. Here, saccharides of both low and high 
Moldability are used to prepare the granules. 
Moldability is the capacity of a compound to be 
compressed. Highly Moldable substance has high 
compressibility and thus slow dissolution. The 
combination of high and low Moldability is used to 
produce tablets of adequate hardness & a rapidly 
melting strong tablet. Active ingredients are mixed 
with low Moldability saccharides and then granulated 
with high Moldability saccharides and then compressed 
into tablet. Wowtab product dissolves quickly in 15 s 
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or less. Wowtab product can be packed in both into 
conventional bottle and blister packs. This technology 
utilizes conventional granulation and tableting methods 
and used for both water-soluble and insoluble drugs. 
The manufacturing process involves granulating low-
moldable sugars (e.g. mannitol, lactose, glucose, 
sucrose, and erythritol) that show quick dissolution 
characteristics with high moldable sugars (e.g. maltose, 
maltitol, and sorbitol). The result is a mixture of 
excipients that have fast-dissolving and highly 
moldable characteristics [1, 12]. 
 
Flashtab (Prographarm) 
Flashtab was developed by Prographarm. A 
disintegrating agent and a swelling agent are used in 
combination with coated taste-masked microgranules 
of drug. FlashTab involves coating a drug with a 
Eudragit polymer to provide rapid release of the drug 
in the stomach, and formulating this microencapsulated 
drug with an effervescent couple to produce a flash 
dispersal tablet. This technology includes granulation 
of excipients by wet or dry granulation method 
followed by compression into tablets. Disintegrating 
agents include polyvinylpyrrolidine or carboxy methyl 
cellulose and Swelling agents include 
carboxymethylcellulose, starch, modified starch, 
microcrystalline cellulose, carboxy methylated starch 
etc. These tablets have satisfactory physical resistance. 
Tablets containing hygroscopic materials can also be 
blister packed using high quality polyvinyl chloride or 
aluminum foils for providing the higher degree of 
moisture protection than normal polyvinyl chloride or 
polypropylene foils [1, 12]. 
 
Durasolv (Cima Labs, Inc.) 
DuraSolv is Cima's second-generation fast-
dissolving/disintegrating tablet formulation. DuraSolv 
has much higher mechanical strength than Orasolv due 
to the use of higher compaction pressures during 
tableting. DuraSolv product is thus produced in a faster 
and more cost-effective manner. DuraSolv is so durable 
that it can be packaged in either traditional blister 
packaging or vials. This technology is not compatible 
with larger doses of active ingredients, because the 
formulation is subjected to such high pressures on 
compaction. Unlike OraSolv, the structural integrity of 
any taste masking may be compromised with high drug 
doses. The drug powder coating in DuraSolv may 
become fractured during compaction, exposing the 
bitter-tasting drug to a patient's taste buds. Therefore, 
DuraSolv technology is best suited for formulations 
including relatively small doses of active compound. 
The tablets made by this technology consist of a drug, 
fillers and a lubricant and prepared by using 
conventional tableting equipment and have good 
rigidity. These can be packed into conventional 
packaging system like blisters. Due to higher force of 
compaction used, tablets prepared are rigid [12]. 
 
Orasolv (Cima Labs, Inc.) 
Orasolv® is Cima’s first orally disintegrating dosage 
form. It based on direct compression of an effervescent 
agent and taste masked drug. The use of effervescence 
causes a tablet to disintegrate rapidly in less than 1 min 
on contact with water or saliva leaving coated drug 
powder. This technique is frequently used to develop 
over the counter formulations. This technology can 
accommodate a wide range of active ingredient from 1 
mg to 500 mg. The effervescence occurs due to 
chemical reaction between organic acid such as citric 
acid, fumaric acid or maleic acid and a base such as 
sodium bicarbonate, potassium bicarbonate, 
magnesium bicarbonate, which result in generation of 
CO2  [39, 40]. 
Effervescent disintegration agents evolve gas by means 
of chemical reaction called effervescent couple. 
Carbonates such as sodium bicarbonate, sodium 
carbonate, potassium bicarbonate and potassium 
carbonate, magnesium carbonate, and acids like citric, 
tartaric, fumaric, adipic and succinic are used. 
Microparticles, effervescent agents and other ingredient 
such as flavors, sweeteners, colorants and lubricants 
are blended and compressed at a low degree of 
compaction [40]. 
 
Frosta (Akina) 
It utilizes the concept of formulating plastic granules 
and compressing them at low pressure to produce 
strong tablets with high porosity. Plastic granules 
composed of porous and plastic material, water 
penetration enhancer, and binder. The process involves 
mixing the porous plastic material with water 
penetration enhancer followed by granulating with 
binder. The tablets obtained have excellent hardness 
and rapid disintegration time ranging from 15 to 30 sec 
depending on size of tablet [41]. 
 
AdvaTab (Eurand) 
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In this technology, microencapsulation process is used 
for coating the drug particles with gastro soluble 
polymer so as to mask the taste along with restriction 
of drug dissolution in mouth cavity. AdvaTab tablets 
disintegrate rapidly in the mouth, typically in less than 
30 seconds. These tablets are especially suited to those 
patients that experience difficulty in swallowing 
capsules and tablets. AdvaTab is distinct from other 
orally disintegrating tablet technologies as it can be 
combined with Eurand’s complimentary particle 
technologies like its world leading Microcaps® (taste-
masking technology) and its Diffucaps® (controlled 
release technology) [41]. 
 
Flashdose (Fuisz Technologies, Ltd.) 
This technology is patented by Fuisz. This uses the 
combination of Shearform and Ceform technologies in 
order to mask the bitter taste of the drug.  
A sugar based matrix, called ‘Floss’, which is made up 
of a combination of crystalline sugars alone or in 
combination with drugs, is used. Floss is self binding 
shearform matrix, which is prepared by flash heat 
processing. FlashDose technology utilizes a unique 
spinning mechanism to produce a floss-like crystalline 
structure, much like cotton candy. This crystalline 
sugar can then incorporate the active drug and be 
compressed into a tablet. This procedure has been 
patented by Fuisz and is known as Shearform. It 
disperses and dissolves quickly. The method has 
certain drawbacks like the dosage form can 
accommodate only up to 600 mg of drug and tablets 
required specialized packing as highly friable, soft and 
moisture sensitive nature. 
Instead of a floss-like material, small spheres of 
saccharides can be produced to carry the drug. The 
process of making microspheres has been patented by 
Fuisz, and is known as Ceform and serves as an 
alternative method of taste masking. Ceform 
technology involves preparation of microspheres of the 
active drug. Drug material alone or in combination 
with other pharmaceutical substances, and excipients is 
placed into a rapidly spinning machine. The centrifugal 
force comes into action, which throws the dry drug 
blend at high speed through small heated openings. 
Due to the heat provided by carefully controlled 
temperature, drug blend liquefies to form a sphere, 
without affecting the drug stability. The formed 
microspheres are compressed into tablet. This 
technique effectively masked the taste of product [12, 
42, 43]. 
 
OraQuick (KV Pharmaceutical Co., Inc.) 
OraQuick utilizes its own patented taste masking 
technology i.e. MicroMask®. In MicroMask® 
technology, taste masking process is done by 
incorporating drug into matrix microsphere. In this 
technique, tablet is prepared by dissolving the sugar 
(sucrose, mannitol, sorbitol, xylose, dextrose, fructose 
or mannose) and protein (albumin or gelatin) in a 
suitable solvent such as water, ethanol, isoproryl 
alcohol and ethanol-water mixture. The solution of 
matrix is then spray dried, yielding highly porous 
granules. Also, utilization of lower heat of production 
is advantageous for heat-sensitive drugs. Granules 
formed then mixed with drug and other excipients and 
compressed at low compression force. KV 
pharmaceuticals claimed that matrix formed protects 
and surrounds the drug powder in microencapsulated 
particles is more reliable during this step [44]. 
 
Nanocrystal Technology (Elan corporation) 
This technology is based on concept that decreasing 
particle size increases the surface area, which leads to 
an increase in dissolution rate. NanoCrystal particles 
are small particles of drug substance, typically less than 
1000 nm in diameter, which are produced by wet 
milling the drug. 
NanoCrystal™ fast dissolving technology provides for: 
• Pharmacokinetic benefits of orally administered 
nanoparticles (<2 microns) in the form of a 
rapidly disintegrating tablet matrix. 
• Product differentiation based upon a 
combination of proprietary and patent-protected 
technology elements. 
• Cost-effective manufacturing processes that 
utilize conventional, scalable unit operations. 
• Exceptional durability, enabling use of 
conventional packaging equipment and formats 
(i.e., bottles and/or blisters). 
• Wide range of doses (up to 200mg of API per 
unit). 
• Utilization of non-moisture sensitive inactives. 
NanoCrystal colloidal dispersions of drug substance are 
combined with water-soluble GRAS (Generally 
Regarded as Safe) ingredients, filled into blisters, and 
lyophilized. The resultant wafers are remarkably 
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robust, yet dissolve in very small quantities of water in 
seconds. This approach avoids manufacturing 
operations (e.g., granulation, blending, and tableting) 
that generate large quantities of aerosolized powder 
and present much higher risk of exposure. The freeze-
drying approach also enables small quantities of drug 
to be converted into orally disintegrating dosage forms 
because manufacturing losses are negligible [45]. 
 
Quick-Dis Technology (Lavipharm) 
Lavipharm Laboratories Inc. has invented an ideal 
intraoral fast-dissolving drug delivery system called as 
Quick-Dis™. This is a thin, flexible, and quick-
dissolving film. The film is placed on the top or the 
floor of the tongue. It is retained at the site of 
application and rapidly releases the active agent for 
local and/or systemic absorption. The Quick-Dis™ 
drug delivery system can be provided in various 
packaging configurations, ranging from unit-dose 
pouches to multiple-dose blister packages. 
Disintegration time is only 5 to 10 seconds for the 
Quick-Dis™ film with a thickness of 2 mm. The 
dissolving time, which is defined as the time at which 
not less than 80% of the tested film is dissolved in 
aqueous media, is around 30 seconds for Quick Dis™ 
film with a thickness of 2 mm. The typical release 
profile of an active ingredient exhibited by a Quick-
Dis™ drug delivery system is 50% released within 30 
seconds and 95% within 1 minute [46]. 
 
EFVDAS (Elan Corporation) 
EFVDAS or Effervescent Drug Absorption System is a 
drug delivery technology that has been used in the 
development of a number of both OTC and prescription 
medications. This is particularly advantageous for 
conditions such as colds and flu, for which Elan has 
modified its EFVDAS technology to develop hot drink 
sachet products that combine medicines and vitamins 
for OTC use. The granular contents of the sachets can 
be added to boiling water to produce pleasant-flavored 
solutions. In these cases the effervescence of the 
granulate mixture is modified to accommodate the use 
of heated water. Examples of products that Elan has 
developed include effervescent ibuprofen, 
acetaminophen, cimetidine, naproxen, and 
acetaminophen and codeine combination product [47]. 
 
Fast Melt (Elan Corporation)  
It is a highly porous, microfine matrix tablet. Once 
placed on the tongue, this matrix rapidly absorbs liquid 
and disintegrates. The drug, in a stabilized, size-
reduced form to ensure optimal solubility, dissolves 
rapidly. The combination of a mild effervescent base 
and drug processing ensures that the dosage form goes 
into solution in approximately 15 to 30 seconds. The 
drug is released rapidly within the oral cavity, where it 
dissolves to form a drug solution that is then 
swallowed. This is particularly advantageous in cases 
like migraine where a fast onset of clinical effect is 
required. A portion of the drug solution may be 
absorbed locally in the oral cavity and therefore may 
avoid first-pass metabolism in the liver that limits the 
bioavailability of many drugs. The fast-melt system 
rapidly disintegrates in the oral cavity; hence, patients 
do not have to swallow a large cumbersome dosage 
form, which discourages many from taking their 
medication. Thus, the fast-melt dosage form combines 
the benefits of liquid formulations with those of a solid 
oral dosage form [47]. 
 
Multiflash (Prographarm) 
Multiflash is a multi-unit tablet composed of coated 
microgranules and fast-disintegrating excipients. This 
multiparticulate tablet quickly disintegrates in the 
esophagus after being swallowed with a minimum 
amount of water. This tablet avoids mucosal adhesion, 
and coated pellets can match various dissolution rates 
[47]. 
 
Conclusion 
Orally disintegrating dosage forms had satisfactorily 
solved the major problem of non-compliance for 
pediatrics and geriatrics which occur mainly because of 
swallowing difficulty. This dosage form has been 
formulated for existing drugs for extending the patent 
life of the drug and also for granting the new patent. 
Majority of drugs can be formulated as orodispersible 
tablets. The safety and efficacy profile of drugs in 
orodispersible tablet is same like their conventional 
tablet dosage form. Based on conventional techniques, 
new techniques are developed like Zydis, WowTab, 
Orasolv and many more, which leads to getting a patent 
and new market strategy for orodispersible tablets. This 
dosage form are gaining market share day by day and 
becoming a better choice of acceptance. 
 
 
Wagh et al. International Journal of Drug Delivery 2 (2010) 98-107 
 
 106
References 
1. Venkateswara SS, Nyshadham JR, Joseph AF. 
Recent technological advances in oral drug delivery 
- a review.  Pharm. Sci. Tech. Today. 2000; 3: 138-
145. 
2. Porter SC. Novel drug delivery: Review of recent 
trends with oral solid dosage forms. Am. Pharm. 
Rev., 2001; 85: 28-35. 
3. Bhushan SY, Sambhaji SP, Anant RP, Mahadik 
KR. New drug delivery system for elderly, Indian 
Drugs 2003; 37: 312-318. 
4. Bandari S, Mittapalli RK, Gannu Rao YM. 
Orodispersible tablet: An overview. Asian J. 
Pharm. 2008; 2: 2-11. 
5. US Food and Drug Administration, CDER Data 
Standards Manual. 2003. 
6. European Pharmacopoeia. 5th ed. Strasbourg, 
France: 2006. p. 628. 
7. Avery SW, Dellarosa DM. Approaches to treating 
dysphagia in patients with brain injury. Am. J. 
Occup. Ther. 1994; 48: 235–239. 
8. Wilson CG. et al. The behavior of a fast dissolving 
dosage form (Expidet) followed by g-scintigraphy. 
Int. J. Pharm. 1987; 40: 119–123. 
9. Kuchekar BS, Badhan AC, Mahajan HS. Mouth 
dissolving tablets: A novel drug delivery system. 
Pharma Times 2003; 35: 7-9. 
10. Bradoo R. Fast Dissolving Drug Delivery Systems. 
J. Am. Med. Asso. 2001; 4 : 27-31. 
11. O’Connor R, Schwartz J. Extrusion and 
spheronization technology. In Pharmaceutical 
Pelletization Technology. Marcel Dekker Inc., 37, 
1989. p. 187. 
12. Agarwal V, Kothari BH, Moe DV, Khankari RK. 
Drug delivery: Fast-dissolve systems. In: Swarbrick 
J, Encyclopedia of pharmaceutical technology. 
New York, USA: Informa Healthcare Inc.; 2006. p. 
1104 –1114. 
13. Fini A, Valentina B, Gian CC, Celestino R, Carlos 
A and Fonseca de M. Fast dispersible/slow 
releasing ibuprofen tablets. Eur. J. Pharm. 
Biopharm. 2008; 69: 335–341. 
14. Masters K. Spray Drying Fundamentals: Process 
stages and Layouts. In: Spray Drying Handbook. 
5th ed.  New York, USA: Longman Scientific and 
Technical; 1991. p. 23–64. 
15. Hughes L. Selecting the right ion exchange resin. 
Pharma Quality 2005; 1: 54–56. 
16. Jeong SH, Park K. Development of sustained 
release fast-disintegrating tablets using various 
polymer-coated ion-exchange resin complexes. Int. 
J. Pharm. 2008; 353: 195–204. 
17. Prasad N, Straus D, Reichart G. Cyclodextrin flavor 
delivery systems. US Patent 6,287,603; 1999. 
18. Venkatesh DP, Geetha Rao CG. Formulation of 
taste masked orodispersible tablets of ambroxol 
hydrochloride. Asian J. Pharm. 2008; 2: 261-264. 
19. Lachman L, Lieberman H, Kanig J. The Theory 
and Practice of Industrial Pharmacy. 3rd ed. Lea 
and Febige; 1986. p. 420. 
20. Virely P, Yarwood R. Zydis – a novel, fast 
dissolving dosage form. Manuf. Chem., 1990, 36–
37. 
21. Seager H. Drug delivery product and the Zydis fast-
dissolving dosage form. J. Pharm. Pharmacol. 
1998; 50: 375-382. 
22. Ahmed IS, Nafadi MM, Fatahalla FA. Formulation 
of fast-dissolving ketoprofen tablet using freeze-
drying in blisters technique. Drug Dev. Ind. Pharm. 
2006; 32: 437-442. 
23. Allen LV, Wang B, Devies JD. Rapidly dissolving 
Tablets. US patent 6,066,337; 2000. 
24. Masaki K. Intrabuccally disintegrating preparation 
and production thereof. US patent 5,466,464; 1995. 
25. Dobetti L. Fast-melting tablets: Developments and 
technologies. Pharm. Tech. Drug Delivery. 2001; 
44-50. 
26. Harmon TM. Orally Disintegrating Tablets: A 
valuable life cycle management strategy. Issue of 
Pharmaceutical Commerce. 2007; 1-4. 
27. Kuno Y, Kojima M, Ando S, Nakagami H. Effect 
of preparation method on properties of orally 
disintegrating tablets made by phase transition. Int. 
J. Pharm. 2008, 355; 87–92. 
28. Abdelbary G, Prinderre P, Eouani C, Joachim J, 
Reynier JP, Piccerelle Ph. The preparation of orally 
disintegrating tablets using a hydrophilic waxy 
binder. Int. J. Pharm. 2004; 278: 423–433. 
29. Perissutti B, Rubessa F, Moneghini M, Voinovich 
D. Formulation design of carbamazepine fast-
release tablets prepared by melt granulation 
technique. Int. J. Pharm. 2003; 256: 53–63. 
30. Koizumi IK et al. New Method of Preparing Highly 
Porous Rapidly saliva Soluble Tablets by 
Sublimation Technique. Int. J. Pharm. 1997; 152: 
127- 131. 
Wagh et al. International Journal of Drug Delivery 2 (2010) 98-107 
 107
31. Makino T, Yamado M, Kikuta JI. Fast Dissolving 
Tablet. US patent 5,720,974; 1998. 
32. Shyamala B, Narmada GV. Rapid dissolving 
tablets: A novel dosage form Indian Pharmacist 
2002; 1 : 9-12. 
33. Chiver TE, Minn O. Process for making candy 
floss. US patent 730057; 2003. 
34. Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, 
Iida K. Preparation and evaluation of a compressed 
tablet rapidly disintegrating in the oral cavity. 
Chem. Pharm. Bull. 1996; 44: 2121-2127. 
35. Cousin G, Bruna E, Gendrot E. Rapidly 
disintegratagable multiparticular tablet, US patent 
5,464,632; 1995. 
36. Gillis PMV, Deconde VFV. Fast-dissolving 
Galanthamine hydrobromide tablet, US patent 
6,099,863; 2000. 
37. Gattani SG, Shiyani BG, Kakade KN, Patil AB, 
Surana SJ. Formulation and development of mouth 
dissolving tablet of Ondensetron hydrochloride by 
using superdisintegrants. Indian drugs. 2009; 46: 
44-50. 
38. Lafon L. Galenic form for oral administration and 
its Method of preparation by lyophillization of an 
oil-in-water emulsion. Euro. Patent 0,159,237; 
1985. 
39. Bankar GS, Anderson NR. Tablets. In: Lanchman 
L, Lieberman HA, Kanig JL. The Theory and 
Practice of Industrial Pharmacy.  Lea & Febiger; 
1987. p. 293–345. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40. Wehling F, Schuehle S, Madamala N. Effervescent 
dosage form with microparticles. US Patent 
5,178,878; 1993. 
41. Kaushik D, Dureja S, Saini TR. An overview of 
melt in mouth tablet technologies and techniques. 
SPI Pharma 2004; 30-35. 
42. Cherukuri SR, Myers GL, Battist GE, Fuisz RC. 
Process for forming quickly dispersing comestible 
unit and product there from. US Patent 5,587,172; 
1996. 
43. Fuisz RC. Ulcer prevention method using a melt-
spun hydrogel. US Patent 5,622,717; 1997. 
44. http://www.uspharmasist.com 
45. http://www.elannanocrystal_technology.htm 
46. Liang AC, Chen, Li-Lan H. Fast-dissolving 
intraoral drug delivery systems. Expert Opinion 
2001; 11: 981-986. 
47. Verma RK, Garg S. Current Status of Drug 
Delivery Technologies and Future Directions. 
Pharm. Tech. On-Line 2001; 25: 9–10. 
 
